Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Memantine Augmentation of Antidepressants

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00344682
Recruitment Status : Completed
First Posted : June 27, 2006
Results First Posted : November 25, 2013
Last Update Posted : July 11, 2018
Forest Laboratories
Information provided by (Responsible Party):
University of Massachusetts, Worcester

Brief Summary:
This study is evaluating the efficacy and safety of the drug memantine (trade name NAMENDA) as an augmentation agent for the treatment of depression in people who are not fully responding to antidepressant medications.

Condition or disease Intervention/treatment Phase
Depressive Disorder Drug: memantine Drug: Placebo Phase 4

Detailed Description:

- Objective

The objective of this study is to evaluate the efficacy and safety of 20 mg of memantine administered once daily as an augmentation agent for subjects who have been taking antidepressants for at least 1 month but who have experienced an incomplete or absent therapeutic response.

- Background

Memantine is a moderate affinity, uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist that is approved for the treatment of moderate-to-severe dementia of the Alzheimer's type. It has been commercially available in 23 countries worldwide since 1982.

There are reports in the published literature that suggest NMDA receptors may be involved in the etiology of depressive disorders. The NMDA antagonist ketamine has been shown to have antidepressant effects in a placebo-controlled clinical trial (Berman et al., 2000). Uncompetitive NMDA receptor antagonists, including memantine, have been shown to exhibit antidepressant-like activity in animal models of depression (Moryl et al., 1993, Papp and Moryl 1994). Animal studies also support the possibility that uncompetitive NMDA receptor antagonists may work synergistically in combination with antidepressants in animal models of depression (Rogoz et al., 2001). Some authors have hypothesized a role for NMDA receptors in the therapeutic effects of numerous antidepressants (Skolnick et al., 1996).

- Study Design and Duration

This is a randomized, single site, double-blind, placebo-controlled, parallel-group study in outpatients. The study consists of an 8-week double-blind treatment period. Approximately 25 patients will be randomized to each treatment group (memantine or placebo) for a total of approximately 50 patients.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 31 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized Double-Blind Pilot Study of Memantine Augmentation in Antidepressant Nonresponders or Incomplete Responders
Study Start Date : June 2006
Actual Primary Completion Date : December 2011
Actual Study Completion Date : December 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Antidepressants

Arm Intervention/treatment
Experimental: memantine
memantine (5-20mg a day)
Drug: memantine
memantine 5mg - 20mg PO daily
Other Name: Namenda

Placebo Comparator: Placebo
placebo (5-20mg a day)
Drug: Placebo
5mg - 20mg PO daily over 8 weeks

Primary Outcome Measures :
  1. Montgomery-Asberg Depression Rating Score (MADRS) [ Time Frame: Baseline & week 8 ]
    Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. Scores 0 to 6 indicate symptoms absent; 7 to 19 indicates mild depression; 30 to 34 defines moderate; 35 to 60 indicates severe depression. Changes in MADRS score was a primary measure.

Secondary Outcome Measures :
  1. Modified Quick Inventory of Depressive Symptoms Self Report Scale (QIDS-SR) [ Time Frame: baseline & week 8 ]
    The 16 item Quick Inventory of Depressive Symptomatology (QIDS-SR16) (Rush et al. 2003) is designed to assess the severity of depressive symptoms, with higher scores representing more severe forms of depression. When complete, the QIDS are scored by summing responses to obtain a total score ranging from 0 to 27. Either appetite increase or decrease, but not both, are used to calculate the total score. Weight increase or decrease, but not both, are used to calculate the total score. Scores 0-5 indicate no severity of depression; 6-10 is mild; 11-15 is moderate; 16-20 is severe; 21-27 is very severe levels of depression. Participants were evaluated at baseline and at weeks 1, 2, 3, 4, 6 & 8.

  2. Hamilton Anxiety Rating Scale (HARS) [ Time Frame: baseline & week 8 ]
    Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Scores > 30 indicate severe anxiety.

  3. Montgomery-Asberg Depression Rating Score (MADRS) [ Time Frame: baseline and week 8 ]
    Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6 on 10 items. The overall score ranges from 0 to 60. Scores 0 to 6 indicate symptoms absent; 7 to 19 indicates mild depression; 30 to 34 defines moderate; 35 to 60 indicates severe depression. Changes in response rate and remission rate were assessed for secondary measures.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female patients between 18 and 85 years of age at screening.
  • Patients must provide written informed consent prior to study entry.
  • Patients must meet DSM-IV-TR (Diagnostic and Statistical Manual IV Text Revision) criteria for Major Depressive Episode of a severity mild, moderate or severe or in partial remission, as confirmed by the MINI.
  • Patients must have a HAM-D (17-item) score of 16 or higher.
  • Patients must have been on 1 of the following medications for 4 or more weeks at or above the listed dose with no psychiatric medication dose changes for the past 25 days:

    • 20 mg qD of fluoxetine (Once Daily)
    • 50 mg qD of sertraline
    • 20 mg qD of paroxetine
    • 200 mg qD of fluvoxamine
    • 20 mg qD of citalopram
    • 10 mg qD of escitalopram
    • 150 mg qD of venlafaxine or venlafaxine sustained release
    • 300 mg qD of bupropion or bupropion sustained or extended release
    • 15 mg qD of mirtazapine
    • 60 mg qD of duloxetine
  • Participants must agree to keep the dose of their existing antidepressant(s) constant throughout the 8-week trial.

Exclusion Criteria:

  • Diagnosis of bipolar disorder or schizophrenic or schizoaffective disorder.
  • History of alcohol or drug abuse or dependence within 6 months of enrollment.
  • Patients who have received ECT (Electroconvulsive Therapy) in the past 3 months.
  • History of seizures.
  • Moderate dementia (MMSE score of 20 or less).
  • Active suicidal ideation: endorsing a 3 (most severe score) on QIDS-SR (Quick Inventory of Depression Symptomatology Self Reports) suicide item OR a score of 2 or higher for the past week on Suicide Scale items 4 or 5 (current suicidal ideation moderate or strong or would avoid taking steps to save life).
  • Currently taking a mood stabilizer or antipsychotic (except lithium clearly used as an augmenting agent).
  • Patients who, in the opinion of the investigator, might not be suitable for the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00344682

Layout table for location information
United States, Massachusetts
Center for Psychopharmacologic Research and Treatment (University of Massachusetts Medical School)
Worcester, Massachusetts, United States, 01605
Sponsors and Collaborators
University of Massachusetts, Worcester
Forest Laboratories
Layout table for investigator information
Principal Investigator: Kristina M Deligiannidis, M.D. University of Massachusetts, Worcester
Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: University of Massachusetts, Worcester Identifier: NCT00344682    
Other Study ID Numbers: NAM-MD-34
First Posted: June 27, 2006    Key Record Dates
Results First Posted: November 25, 2013
Last Update Posted: July 11, 2018
Last Verified: June 2018
Keywords provided by University of Massachusetts, Worcester:
MDD (major depressive disorder)
unipolar depression
uncompetitive NMDA receptor antagonist
Additional relevant MeSH terms:
Layout table for MeSH terms
Depressive Disorder
Mood Disorders
Mental Disorders
Behavioral Symptoms
Antiparkinson Agents
Anti-Dyskinesia Agents
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents